HitGen Inc. (SHA:688222)

China · Delayed Price · Currency is CNY

30.49

-0.78 (-2.49%)

At close: Sep 11, 2026

Market Cap	12.21B +19.6%
Revenue (ttm)	644.54M +40.3%
Net Income	140.14M +53.7%
EPS	0.35 +34.3%
Shares Out	400.68M
PE Ratio	86.73
Forward PE	72.78
Dividend	0.13 (0.41%)
Ex-Dividend Date	Jun 18, 2026

Volume	11,185,870
Open	30.69
Previous Close	31.27
Day's Range	29.60 - 31.12
52-Week Range	21.46 - 42.98
Beta	0.60
Analysts	Strong Buy
Price Target	43.60 (+43.0%)
Earnings Date	Aug 27, 2026

About HitGen

HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; virtual screening; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline also includes HG146, which is in phase Ia clinical trial is a selective HDAC inhibitor for multipl... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2012

Employees 546

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688222

Full Company Profile

Financial Performance

In 2025, HitGen's revenue was 525.57 million, an increase of 23.09% compared to the previous year's 426.99 million. Earnings were 109.51 million, an increase of 113.22%.

Financial Statements

Analyst Summary

According to 5 analysts, the average rating for 688222 stock is "Strong Buy." The 12-month stock price target is ¥43.60, which is an increase of 43.00% from the latest price.

Price Target

¥43.60

(43.00% upside)

Analyst Consensus: Strong Buy

Stock Forecasts